Kane Biotech (CVE:KNE) Hits New 12-Month Low – Here’s Why

Kane Biotech Inc. (CVE:KNEGet Free Report) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as C$0.03 and last traded at C$0.03, with a volume of 305500 shares trading hands. The stock had previously closed at C$0.04.

Kane Biotech Stock Performance

The company’s fifty day moving average is C$0.04 and its 200 day moving average is C$0.04. The company has a market capitalization of C$5.02 million, a P/E ratio of -0.38 and a beta of 0.60. The company has a current ratio of 0.90, a quick ratio of 0.39 and a debt-to-equity ratio of -289.57.

About Kane Biotech

(Get Free Report)

Kane Biotech Inc, a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. The company develops its products using coactiv+ technology, an antimicrobial wound gel platform; and DispersinB technology, a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine for treating wounds and otic infections. It offers revyve, an antimicrobial wound gel; and shampoos, shampoo bars, and scalp detoxifiers under the DermaKB brand.

Featured Stories

Receive News & Ratings for Kane Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kane Biotech and related companies with MarketBeat.com's FREE daily email newsletter.